Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.
Heart drug developer Kardigan files IPO
The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
